) product portfolio as well as pipeline has been strengthened
following its purchase of
) Elan Drug Technologies unit. The company primarily focuses on
developing therapies to treat disorders such as addiction,
schizophrenia and depression, which affect the central nervous
The key marketed products at Alkermes include Risperdal Consta
(schizophrenia and bipolar disorder), Xeplion (schizophrenia),
Vivitrol (opioid and alcohol dependence), Ampyra/Fampyra
(improving walking ability in multiple sclerosis patients) and
Bydureon (type II diabetes).
Alkermes appointed Dr. Serge Stankovic as a senior Vice President
of clinical development and medical affairs to manage the
development of its expanded pipeline more efficiently. The
management team at Alkermes now has another new addition in the
form of Peter Norman. Norman has been recruited as the Vice
President of government affairs and policy. Both Norman and
Stankovic, with their vast experience, are expected to help
Alkermes reach greater heights.
We are pleased with the company's efforts to develop its
pipeline. Interesting candidates include aripiprazole lauroxil
for treating schizophrenia, ALKS 5461 (a combination of ALKS 33
and buprenorphine) for major depressive disorder, ALKS 3831
(schizophrenia) and a three-month formulation of Invega
Alkermes is also advancing the development of the early-stage
candidates in its pipeline. The appointment of Stankovic, who has
donned many important roles pertaining to research and
development in his illustrious career, is expected to be
beneficial to Alkermes' pipeline development efforts. Stankovic
was associated with companies like
AKORN INC (AKRX): Free Stock Analysis Report
ALKERMES INC (ALKS): Free Stock Analysis
ELAN CP PLC ADR (ELN): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.
Alkermes currently carries a Zacks Rank #2 (Buy).
) is another Zacks #2 Ranked stock.